Acute pain is defined as a type of pain that is directly related to soft tissue damage such as sprained ankle. The pain generally lasts for less than 3 to 6 months. The acute pain remains for a short duration of time and is gradually resolved, as the injured tissues heal. The chronic pain is relatively more sharp and severe as compared to acute pain. Acute pain is triggered by a specific disease or injury, skeletal muscle spasm and sympathetic nervous system activation, and is self-limited. The therapy of acute pain is aimed at treating the underlying cause and interrupting the nociceptive signals. The drug treatment of acute pain includes tramadol, gabapentin, Vicodin, oxycodone, oxycontin, ibuprofen and acetaminophen. Some of the drug candidates in the acute pain pipeline include, but are not limited to ORB-101, ATB-352 and Palexia LE.
Some of the key players operating in the acute pain therapeutics pipeline include AcelRx Pharmaceuticals Inc., Syntrix Biosystems Inc., Mallinckrodt Plc, and Orbis Biosciences Inc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.